x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in

science & medicine medicine

All Episodes

00:13:45

Expanding Access to CAR T-Cell Therapy in R/R Myeloma...

Project Oncology® ·

2026/02/13

Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD While BCMA-directed CAR T-cell therapy has changed the treatment landscape for patients with relapsed and refractory (R/R) multiple myeloma, access remains uneven outside academic centers. In this expert-led discussion, Dr. Brian McDonough, Dr. Surbhi Sidana, and Dr. Tara Graff explore real-world barriers to referral and delivery, evolving care models, and the multidisciplinary coordination

en

00:09:00

Tracking Treatment Response: ctDNA Insights in MMR-p...

Project Oncology® ·

2026/02/12

Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found

en

00:04:15

How the First Metastatic Site Shapes Survival in...

Project Oncology® ·

2026/01/29

Presenter: Ryan Quigley Not all metastatic breast cancer is created equal. This AudioAbstract spotlights new data from a multicenter study in Japan that highlights how the first site of distant recurrence can significantly shape a patient’s prognosis. By isolating cases with single-organ metastasis, the study draws sharp contrasts in survival based on metastatic location, revealing that patients with brain or liver involvement fare far worse than those with bone or lung metastases

en

00:14:45

How the 2025 IMWG Guidelines are Reshaping Sequencing...

Project Oncology® ·

2026/01/21

Host: Jennifer Caudle, DO, FACOFP Guest: Mansi R. Shah, MD The latest International Myeloma Working Group (IMWG) guidelines emphasize immune function, relapse timing, and therapeutic intent to guide the sequencing of T-cell-redirecting therapies in relapsed/refractory (R/R) multiple myeloma. Hear key updates as Dr. Jennifer Caudle and Dr. Mansi Shah discuss how we can integrate T-cell redirecting therapies into patient care more intentionally. Dr. Shah is an Associate Professor and

en

00:05:30

Advancing HER2-Targeted Therapy in GI Cancers

Project Oncology® ·

2026/01/20

Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomes in this complex disease setting. Dr. Strickler is a Professor of Medicine in the Division of Medical Oncology at Duke University School of Medicine and

en

00:05:45

How AI Is Transforming Biomarker Development in GI...

Project Oncology® ·

2026/01/16

Guest: William Hall, MD From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains how AI is being applied to data to identify tumor features and treatment susceptibilities faster and more precisely than traditional methods. Dr. Hall is a Professor and Chair of Radiation Oncology at the Medical College of Wisconsin, and he spoke about this topic at the

en

00:04:45

Surgical Insights on Gastroesophageal Cancer:...

Project Oncology® ·

2026/01/16

Guest: Daniela Molena, MD For patients with locally advanced gastroesophageal cancer, surgery remains a critical component of curative treatment—even in the era of chemoradiation and advanced imaging. Dr. Daniela Molena explores the challenges of assessing complete clinical response and the risks of non-operative management. Dr. Molena is an Associate Professor of Surgery at Weill Cornell Medicine and a Thoracic Surgeon at Memorial Sloan Kettering Cancer Center, and she discussed

en

00:11:00

Staying Ahead in mTNBC: First-Line Strategies for an...

Project Oncology® ·

2026/01/14

Host: Jennifer Caudle, DO, FACOFP Guest: Alexis Ann LeVee, MD With a poor prognosis and high disease heterogeneity, metastatic triple-negative breast cancer (mTNBC) demands timely, informed treatment decisions. Dr. Jennifer Caudle is joined by Dr. Alexis LeVee, a breast medical oncologist and clinical instructor at UCLA Health, to explore the importance of early decision-making, the impact of disease heterogeneity, and the evolving data that’s reshaping first-line standards for

en

00:12:45

ctDNA-Guided Immunotherapy Shows Survival Benefit in...

Project Oncology® ·

2025/12/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personalized, tumor-informed ctDNA assay; those testing positive for ctDNA were randomized to receive atezolizumab or placebo,

en

00:07:00

Evaluating PARP and ER Targeting in ER+/HER2– Breast...

Project Oncology® ·

2025/12/22

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer

en

00:04:15

From Resistance to Response: Evolving Treatment...

Project Oncology® ·

2025/12/22

Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest translational insights into resistance mechanisms, including genomic alterations affecting cell cycle and signal transduction pathways, and discusses evolving therapeutic strategies. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School

en

00:12:30

Adjuvant Nivolumab in High-Risk Muscle Invasive...

Project Oncology® ·

2025/12/16

Host: Brian P. McDonough, MD, FAAFP Guest: Matthew Galsky, MD Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial’s long-term data, which show sustained disease-free survival and highlight ctDNA’s potential as a marker for residual disease. These findings reinforce nivolumab’s role in the evolving standard of care and may

en

00:12:00

Tracking Lineage Infidelity in Pediatric B-ALL: New...

Project Oncology® ·

2025/12/16

Host: Ryan Quigley Guest: Kathrin M. Bernt, MD Guest: Rushabh Mehta, BS Guest: Fatemeh Alikarami New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their

en

00:04:45

Beyond the Cure: Addressing Psychosocial Needs in...

Project Oncology® ·

2025/12/10

Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victoria Coleman-Cowger as she highlights recommendations for supporting emotional wellbeing during and after gene therapy and explains the importance of recognizing both the psychological and social impacts of curative treatment. Dr. Coleman-Cowger is a

en

00:03:45

Reducing Endometrial Cancer Risk: Targeting...

Project Oncology® ·

2025/12/10

Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. Dr. Brian Slomovitz discusses how lifestyle interventions and emerging therapies may reduce cancer recurrence. He’s the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor

en

00:03:30

Unmet Needs in Endometrial Cancer: Bridging Gaps in...

Project Oncology® ·

2025/12/10

Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida

en

00:00:00

Selecting First-Line Therapy in Gastric Cancers: A...

Project Oncology® ·

2025/11/10

Host: Jennifer Caudle, DO Guest: Samuel Klempner, MD Guest: Nataliya Uboha, MD, PhD Testing for biomarkers like PD-L1, HER2, claudin 18.2, and FGFR2b is reshaping our approach to first-line therapy in advanced gastric and gastroesophageal junction cancers. Alongside biomarker profiling, we must also weigh practical considerations around efficacy, toxicity, and patient-specific factors when selecting treatment. Joining Dr. Jennifer Caudle to explore how we can optimize our

en

00:00:00

Managing MCL After BTKi Failure: The Expanding Role...

Project Oncology® ·

2025/10/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing

en

00:00:00

Reevaluating Race in Spirometry: Advancing Equity in...

Project Oncology® ·

2025/10/21

Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction, and highlights the need for data-driven, continuous risk assessment tools in caring for patients with non-small cell lung cancer. Dr. Sheshadri is an Associate Professor in the Department of

en

00:00:00

Modernizing Pulmonary Assessment: Reassessing...

Project Oncology® ·

2025/10/21

As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.

en

171 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事